264 related articles for article (PubMed ID: 17444026)
1. Issues in the interpretation of 180-day exclusivity.
Lietzan E; Korn DE
Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
[No Abstract] [Full Text] [Related]
2. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
Lietzan EK
Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
[TBL] [Abstract][Full Text] [Related]
3. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
4. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
5. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
Lietzan EK
Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
[TBL] [Abstract][Full Text] [Related]
6. A new history and discussion of 180-day exclusivity.
Korn DE; Lietzan E; Scott SW
Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
[TBL] [Abstract][Full Text] [Related]
7. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
8. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
9. FDA's role in making exclusivity determinations.
Dickinson EH
Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
[No Abstract] [Full Text] [Related]
10. GATT implementation and generic drug approval.
Safir PO; Lassman SM
Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
[No Abstract] [Full Text] [Related]
11. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
12. Pediatric marketing exclusivity--as altered by the Best Pharmaceuticals for Children Act of 2002.
Cooper KJ
Food Drug Law J; 2002; 57(3):519-44. PubMed ID: 12710409
[No Abstract] [Full Text] [Related]
13. Fifty years of drug amendments revisited: in easy-to-swallow capsule form.
Kaplan AH
Food Drug Law J; 1995; 50 Spec():179-96. PubMed ID: 10343042
[No Abstract] [Full Text] [Related]
14. The History and Political Economy of the Hatch-Waxman Amendments.
Lietzan E
Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
[No Abstract] [Full Text] [Related]
15. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
[TBL] [Abstract][Full Text] [Related]
16. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
17. The right to a jury trial in actions under the Waxman-Hatch Act.
Coggio BD; Bresnick SA
Food Drug Law J; 1997; 52(3):259-76. PubMed ID: 10343025
[No Abstract] [Full Text] [Related]
18. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
19. The right to a jury trial under the Waxman-Hatch Act--the question revisited and resolved.
Coggio BD; DeMasi TE
Food Drug Law J; 2002; 57(1):155-60. PubMed ID: 12118478
[No Abstract] [Full Text] [Related]
20. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
[No Abstract] [Full Text] [Related]
[Next] [New Search]
